Stephen Lockhart | Director
Hurst Grange Associates

I qualified in Medicine from the University of Oxford in 1980. After working around the UK in hospital medicine and research, I joined the pharmaceutical industry in 1986. I am a Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences. For over 30 years I have been engaged in global vaccine clinical R&D across all phases, in Lederle, Wyeth, Emergent BioSolutions, sanofi-pasteur MSD, and most recently Pfizer. I was involved with bringing some major vaccines to the clinic, including the first pneumococcal and the first meningococcal conjugate vaccines and the first modRNA COVID-19 vaccine, but have also learnt much from less successful developments. I am currently a consultant with Hurst Grange Associates, stephenlockhart@hurstgrangeassociates.co.uk.

Appearances:

Day 2 - Wednesday 15th October @ 15:45

Comparative analysis of evidence generation approaches for vaccines in outbreak settings

Significant progress in research on arboviruses and flaviviruses; dengue, tick-borne encephalitis, yellow fever
Evolving regulatory approaches for trials, adapting to new technologies and global health challenges
Chikungunya case study; navigating multi-country licensure challenges and innovative regulatory approaches
Evidence generation under pressure; balancing urgent public health needs with trial rigour
Post-licensure trials in non-licensed markets; regulatory, ethical and operational complexities
How global regulators are evolving approaches to support both emergency responses and robust scientific evaluation during outbreaks

Jakob Cramer, Head Of Clinical Development, CEPI

Rosybel Drury, Senior Director, MSD

RAJESHWARI ADHISESHAN, senior program officer, Bill and Melinda Gates Foundation

Manuela Mura, scientific officer, European Medicines Agency

Moderator: Stephen Lockhart, Director, Hurst Grange Associates

Julia Djonova, Head of ATMP division, Swissmedic

Day 3 - Thursday 16th October @ 14:00

Panel: Challenge Models in Vaccine Development — From Established Tools to Emerging Frontiers

Leveraging proven challenge models: what are we learning and how are they being applied in modern trials?
Exploring new and proposed challenge models: assessing scientific value, safety, and ethical boundaries

Moderator: Stephen Lockhart, Director, Hurst Grange Associates

Dimitri Diavatopoulos, Associate Professor, Radboud Center for Infectious Diseases